NO20043842L - New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX - Google Patents
New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IXInfo
- Publication number
- NO20043842L NO20043842L NO20043842A NO20043842A NO20043842L NO 20043842 L NO20043842 L NO 20043842L NO 20043842 A NO20043842 A NO 20043842A NO 20043842 A NO20043842 A NO 20043842A NO 20043842 L NO20043842 L NO 20043842L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- processes
- forms
- atorvastatin hemicalcium
- new
- Prior art date
Links
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title 2
- 238000000034 method Methods 0.000 title 2
- 239000013078 crystal Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35718102P | 2002-02-15 | 2002-02-15 | |
| US42532502P | 2002-11-12 | 2002-11-12 | |
| PCT/US2003/005384 WO2003070702A1 (en) | 2002-02-15 | 2003-02-19 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043842L true NO20043842L (en) | 2004-09-14 |
Family
ID=27760457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043842A NO20043842L (en) | 2002-02-15 | 2004-09-14 | New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1480950A4 (en) |
| JP (2) | JP2005519076A (en) |
| KR (1) | KR100724515B1 (en) |
| CN (1) | CN100406436C (en) |
| AU (1) | AU2003217653A1 (en) |
| CA (1) | CA2475864A1 (en) |
| DE (1) | DE03713610T1 (en) |
| ES (1) | ES2241507T1 (en) |
| HR (1) | HRP20040768A2 (en) |
| IS (1) | IS7402A (en) |
| MX (1) | MXPA04007939A (en) |
| NO (1) | NO20043842L (en) |
| PL (1) | PL372303A1 (en) |
| WO (1) | WO2003070702A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| JP4422488B2 (en) | 2002-02-19 | 2010-02-24 | テバ ファーマシューティカル インダストリーズ リミティド | Desolvation method of atorvastatin hemi-calcium solvate and atorvastatin hemi-calcium essentially free of organic solvent |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| CA2754932C (en) | 2004-07-20 | 2014-04-01 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| DE05774589T1 (en) * | 2004-07-22 | 2007-08-09 | Teva Pharmaceutical Industries Ltd. | NEW CRYSTAL FORMS OF ATORVASTATIN HEMI CALCIUM AND METHOD FOR THE PRODUCTION THEREOF |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| JP5523699B2 (en) * | 2005-04-08 | 2014-06-18 | エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ | A new crystalline polymorph of atorvastatin hemi-calcium salt |
| ES2304335T3 (en) | 2005-11-21 | 2010-05-19 | Warner-Lambert Company Llc | NEW FORMS OF ACID (R- (R *, R *)) - 2- (4-FLUOROPHENYL) -B, B-DIHYDROXI-5- (1-METHYLETY) -3-PHENYL-4 - ((PHENYLAMINE) CARBON) 1H-PIRROL-1-HEPTANOIC, OF MAGNESIUM. |
| US8080672B2 (en) | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| KR101012917B1 (en) | 2007-03-02 | 2011-02-08 | 동아제약주식회사 | Novel Crystalline Form of Pyrrole Heptanoic Acid Compound |
| KR20120011249A (en) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | Novel crystalline forms of atorvastatin hemicalcium salts, hydrates thereof, and methods for preparing the same |
| KR101324862B1 (en) * | 2011-07-12 | 2013-11-01 | (주)에이에스텍 | Spherical particle of clopidogrel bisulfate, pharmaceutical composition comprising the same and method of preparation thereof |
| TWI665190B (en) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | Solid form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, composition and use thereof |
| CN105055357A (en) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | Atorvastatin calcium composition tablet for treating hypercholesteremia |
| KR101723783B1 (en) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9609872A (en) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi calcium salt of (R- (R * R *)) - 2- (4-fluorophenyl -) - beta delta-dihydroxy-5- (1-methylethyl) -3-phenyl-4- [(phenylamino) carbonyl ] -1H- pyrrole-1heptanoic (atorvastatin) and ristaline |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| SI1535613T1 (en) * | 1999-11-17 | 2010-12-31 | Teva Pharma | Process for preparing a polymorphic form of atorvastatin calcium |
| EP1242373B1 (en) * | 1999-12-17 | 2006-03-15 | Pfizer Science and Technology Ireland Limited | A process for producing crystalline atorvastatin calcium |
| CA2388226A1 (en) * | 1999-12-17 | 2001-06-21 | William Tully | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
| CN1535139A (en) * | 2000-11-03 | 2004-10-06 | ������ҩ��ҵ����˾ | Atorvastatin hemi-calcium form VII |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2431068C (en) * | 2000-12-27 | 2008-06-10 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of atorvastatin |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| HUP0400381A2 (en) * | 2001-06-29 | 2004-09-28 | Warner-Lambert Company Llc | Crystalline forms of r-(r*,r*)-2-(4-fluorphenyl)-betha, delta dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylaminocarbonyl-iii-pyrrole-1-heptanoic acid calcium salt (2:1)(atorvastatin) |
| JP2005500351A (en) * | 2001-07-30 | 2005-01-06 | ドクター・レディーズ・ラボラトリーズ・リミテッド | Atorvastatin calcium in crystalline form VI and VII |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| WO2004022053A1 (en) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
-
2003
- 2003-02-19 PL PL03372303A patent/PL372303A1/en not_active Application Discontinuation
- 2003-02-19 CA CA002475864A patent/CA2475864A1/en not_active Abandoned
- 2003-02-19 DE DE03713610T patent/DE03713610T1/en active Pending
- 2003-02-19 JP JP2003569609A patent/JP2005519076A/en not_active Withdrawn
- 2003-02-19 KR KR1020047012591A patent/KR100724515B1/en not_active Expired - Fee Related
- 2003-02-19 CN CNB038082071A patent/CN100406436C/en not_active Expired - Fee Related
- 2003-02-19 MX MXPA04007939A patent/MXPA04007939A/en unknown
- 2003-02-19 WO PCT/US2003/005384 patent/WO2003070702A1/en not_active Ceased
- 2003-02-19 ES ES03713610T patent/ES2241507T1/en active Pending
- 2003-02-19 EP EP03713610A patent/EP1480950A4/en not_active Withdrawn
- 2003-02-19 HR HR20040768A patent/HRP20040768A2/en not_active Application Discontinuation
- 2003-02-19 AU AU2003217653A patent/AU2003217653A1/en not_active Abandoned
-
2004
- 2004-08-13 IS IS7402A patent/IS7402A/en unknown
- 2004-09-14 NO NO20043842A patent/NO20043842L/en not_active Application Discontinuation
-
2009
- 2009-06-08 JP JP2009137400A patent/JP2009235083A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20040768A2 (en) | 2005-06-30 |
| DE03713610T1 (en) | 2005-10-20 |
| WO2003070702A1 (en) | 2003-08-28 |
| KR100724515B1 (en) | 2007-06-04 |
| PL372303A1 (en) | 2005-07-11 |
| IS7402A (en) | 2004-08-13 |
| ES2241507T1 (en) | 2005-11-01 |
| JP2009235083A (en) | 2009-10-15 |
| CN100406436C (en) | 2008-07-30 |
| EP1480950A4 (en) | 2005-05-18 |
| JP2005519076A (en) | 2005-06-30 |
| MXPA04007939A (en) | 2004-11-26 |
| AU2003217653A1 (en) | 2003-09-09 |
| CA2475864A1 (en) | 2003-08-28 |
| KR20040081202A (en) | 2004-09-20 |
| EP1480950A1 (en) | 2004-12-01 |
| CN1646490A (en) | 2005-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032425D0 (en) | New crystal forms of atorvastatin hemi-calcium and methods for their preparation, as well as new methods for the preparation of other forms | |
| NO20035193D0 (en) | New pyrrole derivatives as pharmaceuticals | |
| NO20034187D0 (en) | Novel spirotric cyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
| DK1701946T3 (en) | 1-piperazine and 1-homopiperazine carboxylate derivatives, their preparation and their therapeutic use as inhibitors of the FAAH enzyme | |
| NO20043726L (en) | Heteroaryl compounds useful as inhibitors of GSK-3 | |
| NO20061396L (en) | New heterocyclic compounds as HSP90 inhibitors | |
| NO20040933L (en) | Novel gamma-secretase inhibitors. | |
| IS7768A (en) | Methods for the production, isolation and purification of epothilone B, and the X-ray crystal structures of epothilone B | |
| DK1636228T3 (en) | Novel pyridopyrazines and their use as kinase modulators | |
| NO20050665L (en) | Pyrrolidone derivatives as MAOE inhibitors | |
| DK1668001T3 (en) | Substituted heteroarylbenzofuranic acids | |
| ATE486597T1 (en) | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | |
| IS7402A (en) | New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IX | |
| NO20054876D0 (en) | Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as drug and drug containing such compounds | |
| NO20045554L (en) | Procedure for the treatment of diabetes | |
| NO20062021L (en) | Redirected pentanols, their methods of preparation, and their use as antiflogistics | |
| HRP20150163T1 (en) | PROCEDURE FOR THE PRODUCTION OF N-SUBSTITUTED 2-CYANOPYROLIDINE | |
| NO20040996L (en) | New Compounds and Compositions as Catepsin Inhibitors | |
| NO20035328D0 (en) | New compounds and preparations as catheps inhibitors | |
| NO331195B1 (en) | Process for the preparation of halogen-substituted monosulfides and their hydroxymonosulfide equivalents as intermediates. | |
| DE602004023786D1 (en) | Production of high purity alkylgallium | |
| EA200501900A1 (en) | NEW METHOD OF SYNTHESIS PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | |
| NO20044332L (en) | Improved process for the preparation of nevirapine | |
| DK1511724T3 (en) | Process for the preparation of thioalkylamine derivatives | |
| EA200600455A1 (en) | NEW METHOD OF SYNTHESIS PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |